New Antibody-Drug combo targets Hard-to-Treat digestive cancers
NCT ID NCT05628857
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a drug called RC108 in 29 people with advanced digestive system cancers that have a protein called c-Met. RC108 is an antibody-drug combination given through a vein. The study looked at how well the drug shrinks tumors and what side effects occur. Results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RC108 (an antibody-drug combination given by IV)
What this could lead to
If successful, RC108 could offer a new treatment option for people with advanced digestive cancers that have a specific marker (c-Met).
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGESTIVE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hopspital
Beijing, Beijing Municipality, 000000, China